Bardoxolone Methyl Inhibits the Infection of Rabies Virus Via Nrf2 Pathway Activation in Vitro

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2023 Nov 11

PMID 37950261

Authors

Ying Lin Chi

Yuan Xie

Shu Qing Liu

Wu Yang Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Rabies is a widespread, fatal, infectious disease. Several antivirals against rabies virus (RABV) infection have been reported, but no approved, RABV-specific antiviral drugs that inhibit RABV infection in the clinic after symptom onset are available. Therefore, more effective drugs to reduce rabies fatalities are urgently needed. Bardoxolone methyl (CDDO-Me), an FDA-approved compound that has long been known as an antioxidant inflammatory modulator and one of the most potent nuclear factor erythroid-derived 2-like 2 (Nrf2) activators, protects myelin, axons, and CNS neurons by Nrf2 activation. Therefore, we investigated the potency of its anti-RABV activity in vitro.

Methods: The mouse neuroblastoma cell line Neuro2a (N2a) and three RABV strains of different virulence were used; the cytotoxicity and anti-RABV activity of CDDO-Me in N2a cells were evaluated by CCK-8 assay and direct fluorescent antibody (DFA) assay. Pathway activation in N2a cells infected with the RABV strains SC16, CVS-11 or CTN upon CDDO-Me treatment was evaluated by western blotting (WB) and DFA assay.

Results: CDDO-Me significantly inhibited infection of the three RABV strains of differing virulence (SC16, CVS-11 and CTN) in N2a cells. We also examined whether CDDO-Me activates the Nrf2-associated pathway upon infection with RABV strains of differing virulence. Nrf2, phosphorylated sequestosome (SQSTM1), SQSTM1, hemoglobin oxygenase (HO-1) and NAD(P)H dehydrogenase quinone 1 (NQO1) expression in N2a cells increased to varying degrees with CDDO-Me treatment, accompanied by Kelch-like ECH-associated protein 1 (Keap1) dissociation, upon infection with SC16, CVS-11 or CTN. The activation of SQSTM1 phosphorylation was significantly associated with the degradation of Keap-1 in CDDO-Me-treated N2a cells upon RABV infection. Furthermore, N2a cells pretreated with the Nrf2-specific inhibitor ATRA showed a significant decrease in HO-1 and NQO1 expression and a decrease in the anti-RABV efficacy of CDDO-Me. These inhibitory effects were observed upon infection with three RABV strains of differing virulence.

Conclusion: CDDO-Me inhibited RABV infection via Nrf2 activation, promoting a cytoprotective defense response in N2a cells. Our study provides a therapeutic strategy for RABV inhibition and neuroprotection during viral infection.

Citing Articles

Human Rabies Treatment-From Palliation to Promise.

Lacy M, Phasuk N, Scholand S Viruses. 2024; 16(1).

PMID: 38275970 PMC: 10819634. DOI: 10.3390/v16010160.

References

Sun Q, Ye F, Liang H, Liu H, Li C, Lu R . Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021; 6(1):212. PMC: 8164054. DOI: 10.1038/s41392-021-00628-x. View

Lehmann E, El-Tantawy W, Ocker M, Bartenschlager R, Lohmann V, Hashemolhosseini S . The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology. 2010; 51(2):398-404. DOI: 10.1002/hep.23339. View

Shigdel U, Lee S, Sowa M, Bowman B, Robison K, Zhou M . Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface. Proc Natl Acad Sci U S A. 2020; 117(29):17195-17203. PMC: 7382241. DOI: 10.1073/pnas.2006560117. View

Atilano-Roque A, Aleksunes L, Joy M . Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury. Toxicol Lett. 2016; 259:52-59. DOI: 10.1016/j.toxlet.2016.07.021. View

Linker R, Lee D, Ryan S, van Dam A, Conrad R, Bista P . Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011; 134(Pt 3):678-92. DOI: 10.1093/brain/awq386. View

Smith T, Jackson F, Morgan C, Carson W, Martin B, Gallardo-Romero N . Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro. Viruses. 2020; 12(2). PMC: 7077210. DOI: 10.3390/v12020177. View

Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J . Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016; 73(17):3221-47. PMC: 4967105. DOI: 10.1007/s00018-016-2223-0. View

Banyard A, Mansfield K, Wu G, Selden D, Thorne L, Birch C . Re-evaluating the effect of Favipiravir treatment on rabies virus infection. Vaccine. 2017; 37(33):4686-4693. DOI: 10.1016/j.vaccine.2017.10.109. View

Lu M, Ji J, Jiang Z, You Q . The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016; 36(5):924-63. DOI: 10.1002/med.21396. View

10.

Yamamoto M, Kensler T, Motohashi H . The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev. 2018; 98(3):1169-1203. PMC: 9762786. DOI: 10.1152/physrev.00023.2017. View

11.

Schwarz K . Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996; 21(5):641-9. DOI: 10.1016/0891-5849(96)00131-1. View

12.

Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky S, Gautam S . Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol. 2007; 84(2):147-57. DOI: 10.1007/s11060-007-9364-9. View

13.

Zhang H, Li H, Zhou Y, Wu M, Zhou H . Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation. Free Radic Biol Med. 2009; 47(3):261-8. DOI: 10.1016/j.freeradbiomed.2009.04.028. View

14.

Alandijany T, Kammouni W, Roy Chowdhury S, Fernyhough P, Jackson A . Mitochondrial dysfunction in rabies virus infection of neurons. J Neurovirol. 2013; 19(6):537-49. DOI: 10.1007/s13365-013-0214-6. View

15.

Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K . p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016; 7:12030. PMC: 4931237. DOI: 10.1038/ncomms12030. View

16.

Lee D, Park J, Lee Y, Han J, Lee D, Kwon S . SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity. Autophagy. 2020; 16(11):1949-1973. PMC: 7595589. DOI: 10.1080/15548627.2020.1712108. View

17.

Yu P, Tao X, Wang L, Tang Q, Liu S, Zhu W . [Preparation and Preliminary Application of a Virus Library for the Neutralizing Activity of a Monoclonal Antibody Against the Rabies Virus]. Bing Du Xue Bao. 2018; 32(6):790-5. View

18.

Hart R, Pearce L, Aguilar M . Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-67. DOI: 10.7326/0003-4819-146-12-200706190-00007. View

19.

Dinkova-Kostova A, Liby K, Stephenson K, Holtzclaw W, Gao X, Suh N . Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A. 2005; 102(12):4584-9. PMC: 555528. DOI: 10.1073/pnas.0500815102. View

20.

Carvajal-Yepes M, Himmelsbach K, Schaedler S, Ploen D, Krause J, Ludwig L . Hepatitis C virus impairs the induction of cytoprotective Nrf2 target genes by delocalization of small Maf proteins. J Biol Chem. 2011; 286(11):8941-51. PMC: 3058995. DOI: 10.1074/jbc.M110.186684. View